Tobias Reichlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tobias Reichlin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Christian Mueller
4 shared publications- Christian Puelacher
Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel , Spitalstrasse 2, 4056 Basel, Switzerland
3 shared publications - Christian Sticherling
Department of Cardiology, University Hospital Basel, University Basel , Basel
3 shared publications Jasper Boeddinghaus
3 shared publications- Karin Wildi
University Hospital Basel, University of Basel
3 shared publications - Raphael Twerenbold
Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
3 shared publications
Latest Publications
- 20 February 2015
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 26 (4) , 390-396
Feasibility, Efficacy, and Safety of Radiofrequency Ablation of Atrial Fibrillation Guided by Monitoring of the Initial Impedance Decrease as a Surrogate of Catheter Contact
AF Ablation Guided by Initial Impedance Drop: Background: The initial impedance decrease during radiofrequency (RF) ablation is an indirect marker of catheter contact and lesion formation. We aimed to assess feasibility, efficacy, and safety of an ablation approach guided by initial impedance decrease.Methods: A total of 25 patients with paroxysmal AF had point‐by‐point, wide antral pulmonary vein (PV) isolation. RF applications were aborted if a decrease of at least 5 Ω did not occur in the first 10 seconds; otherwise, ablation was continued for at least 20 seconds. Power was 30 Watts and reduced to 15–25 Watts on the posterior wall.Results: A total of 28% of RF applications were terminated because of inadequate impedance decrease. The remaining lesions showed a median decrease of 7.6 Ω (IQR 5.0–10.7) at 10 seconds and median duration of RF lesions was 38 seconds. Note that, 100 PVs were isolated with 49 rings. PVI occurred before anatomic completion of the ablation ring of adequate lesions in 39/49 (80%) and concurrent with ring completion in 7/49 (14%). Additional lesions were required in 3/49 (6%) rings. After PVI, additional lesions were required to eliminate dormant conduction in 2/47 (4%) and pace‐capture on the ablation line in 24/49 vein pairs (49%). During short‐term follow‐up, 3 nonfatal esophageal injuries and 2 late pericardial effusions occurred. During a mean follow‐up of 431 ± 87 days, 21/25 patients (84%) remained free of recurrent symptomatic atrial arrhythmias.Conclusions: PVI guided by initial impedance decrease is feasible and results in PVI concurrent with or before completion of the ablation ring in 94% of patients. Single procedure efficacy after one year of follow‐up was 84%. Near‐term complications suggest that deeper lesions are created, indicating that further reduction of RF‐power and duration is warranted.
- 20 February 2015
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 26 (4) , 390-396
Feasibility, Efficacy, and Safety of Radiofrequency Ablation of Atrial Fibrillation Guided by Monitoring of the Initial Impedance Decrease as a Surrogate of Catheter Contact
AF Ablation Guided by Initial Impedance Drop: Background: The initial impedance decrease during radiofrequency (RF) ablation is an indirect marker of catheter contact and lesion formation. We aimed to assess feasibility, efficacy, and safety of an ablation approach guided by initial impedance decrease.Methods: A total of 25 patients with paroxysmal AF had point‐by‐point, wide antral pulmonary vein (PV) isolation. RF applications were aborted if a decrease of at least 5 Ω did not occur in the first 10 seconds; otherwise, ablation was continued for at least 20 seconds. Power was 30 Watts and reduced to 15–25 Watts on the posterior wall.Results: A total of 28% of RF applications were terminated because of inadequate impedance decrease. The remaining lesions showed a median decrease of 7.6 Ω (IQR 5.0–10.7) at 10 seconds and median duration of RF lesions was 38 seconds. Note that, 100 PVs were isolated with 49 rings. PVI occurred before anatomic completion of the ablation ring of adequate lesions in 39/49 (80%) and concurrent with ring completion in 7/49 (14%). Additional lesions were required in 3/49 (6%) rings. After PVI, additional lesions were required to eliminate dormant conduction in 2/47 (4%) and pace‐capture on the ablation line in 24/49 vein pairs (49%). During short‐term follow‐up, 3 nonfatal esophageal injuries and 2 late pericardial effusions occurred. During a mean follow‐up of 431 ± 87 days, 21/25 patients (84%) remained free of recurrent symptomatic atrial arrhythmias.Conclusions: PVI guided by initial impedance decrease is feasible and results in PVI concurrent with or before completion of the ablation ring in 94% of patients. Single procedure efficacy after one year of follow‐up was 84%. Near‐term complications suggest that deeper lesions are created, indicating that further reduction of RF‐power and duration is warranted.
- 1 February 2014
- Published by Elsevier in Heart Rhythm
- Vol. 11 (2) , 194-201
Initial impedance decrease as an indicator of good catheter contact: Insights from radiofrequency ablation with force sensing catheters
- 1 February 2014
- Published by Elsevier in Heart Rhythm
- Vol. 11 (2) , 194-201
Initial impedance decrease as an indicator of good catheter contact: Insights from radiofrequency ablation with force sensing catheters
- 2 April 2012
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 17 (6) , e10
Serial changes in highly sensitive cardiac troponin improve the early diagnosis of acute myocardial infarction
The recently introduced highly sensitive cardiac troponin (hsTn) assays have been shown to improve the diagnostic accuracy in the early diagnosis of acute myocardial infarction (AMI).1 , 2 Improvements in assay sensitivity however have significantly increased the number of positive hsTn tests in various conditions other than AMI. Utilisation of troponin changes to differentiate acute from chronic troponin elevations have been proposed to overcome this diagnostic challenge.3
- 2 April 2012
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 17 (6) , e10
Serial changes in highly sensitive cardiac troponin improve the early diagnosis of acute myocardial infarction
The recently introduced highly sensitive cardiac troponin (hsTn) assays have been shown to improve the diagnostic accuracy in the early diagnosis of acute myocardial infarction (AMI).1 , 2 Improvements in assay sensitivity however have significantly increased the number of positive hsTn tests in various conditions other than AMI. Utilisation of troponin changes to differentiate acute from chronic troponin elevations have been proposed to overcome this diagnostic challenge.3
- 1 February 2012
- Published by Elsevier in Heart Rhythm
- Vol. 9 (2) , 315-316
Retrograde placement of a defibrillator lead through the pulmonary valve
- 1 February 2012
- Published by Elsevier in Heart Rhythm
- Vol. 9 (2) , 315-316
Retrograde placement of a defibrillator lead through the pulmonary valve
- 29 May 2011
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 104 (10) , 849-857
Characterization and financial impact of implantable cardioverter-defibrillator patients without interventions 5 years after implantation
Background: Implantable cardioverter defibrillators (ICD’s) are increasingly used for primary and secondary prevention of sudden cardiac death. However, data on how many ICD patients indeed receive appropriate ICD therapy during long-term follow-up is scarce.
- 29 May 2011
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 104 (10) , 849-857
Characterization and financial impact of implantable cardioverter-defibrillator patients without interventions 5 years after implantation
Background: Implantable cardioverter defibrillators (ICD’s) are increasingly used for primary and secondary prevention of sudden cardiac death. However, data on how many ICD patients indeed receive appropriate ICD therapy during long-term follow-up is scarce.